Early effects of human papillomavirus vaccination in Belgium

被引：11

作者：

Merckx, Mireille ^{[1
,2
]}

Vanden Broeck, Davy ^{[1
]}

Benoy, Ina ^{[3
]}

Depuydt, Christophe ^{[3
]}

Weyers, Steven ^{[2
]}

Arbyn, Marc ^{[4
]}

机构：

[1] Univ Ghent, ICRH, B-9000 Ghent, Belgium

[2] Ghent Univ Hosp, Dept Obstet & Gynaecol, Ghent, Belgium

[3] Son Hlth Care AML, Antwerp, Belgium

[4] Sci Inst Publ Hlth, Canc Epidemiol Unit, Brussels, Belgium

来源：

EUROPEAN JOURNAL OF CANCER PREVENTION | 2015年 / 24卷 / 04期

关键词：

CROSS-PROTECTIVE EFFICACY; GRADE CERVICAL LESIONS; METAANALYSIS; PREVENTION; INFECTION; CANCER;

D O I：

10.1097/CEJ.0000000000000067

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Human papillomavirus (HPV) vaccination has been reimbursed in Belgium since 2007 for girls (12-15 years), extended to girls up to 18 years in 2008. This study assesses the trend of HPV 16/18 infections in women less than 25 years of age participating in opportunistic cervical cancer screening. A significant reduction in the prevalence of HPV 16 [relative risk (RR)=0.61, 95% confidence interval=0.39-0.95] and a nonsignificant reduction in HPV 18 (RR=0.65, 95% confidence interval=0.29-1.48) was found in the youngest group (15-19 years). The prevalences in the older age group did not change significantly. These findings show the early effects of HPV vaccination and confirm the effectiveness of immunization in a real-life setting.

引用

页码：340 / 342

页数：3

共 50 条

[1] Introduction of Human Papillomavirus Vaccination in Belgium, Luxembourg and the Netherlands
Arbyn, M.
Simoens, C.
Van Damme, P.
Scharpantgen, A.
Meijer, C. J. L. M.
Beutels, P.
GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 2010, 70 (04) : 224 - 232
[2] Cost-Effectiveness Evaluation of a Quadrivalent Human Papillomavirus Vaccine in Belgium
Annemans, Lieven
Remy, Vanessa
Oyee, James
Largeron, Nathalie
PHARMACOECONOMICS, 2009, 27 (03) : 231 - 245
[3] Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico
Ortiz, Ana Patricia
Ortiz-Ortiz, Karen J.
Rios, Moraima
Laborde, Jose
Kulkarni, Amit
Pillsbury, Matthew
Lauschke, Andreas
Monsanto, Homero A.
Marques-Goyco, Cecile
PLOS ONE, 2017, 12 (11):
[4] Human Papillomavirus: Oral Lesions and Vaccination
Di Spirito, Federica
CANCERS, 2023, 15 (10)
[5] Human papillomavirus vaccination in adolescence
Russell, Michelle
Raheja, Vinita
Jaiyesimi, Rotimi
PERSPECTIVES IN PUBLIC HEALTH, 2013, 133 (06) : 320 - 324
[6] Monitoring of human papillomavirus vaccination
Dillner, J.
Arbyn, M.
Unger, E.
Dillner, L.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2011, 163 (01) : 17 - 25
[7] Age of human papillomavirus vaccination?
Castle, Philip E.
Burger, Emily A.
LANCET INFECTIOUS DISEASES, 2016, 16 (10) : 1091 - 1093
[8] Vaccination for the Human Papillomavirus
Agueero Echeverria, Wilson Martin
PEDIATRIA-ASUNCION, 2013, 40 (02): : 167 - 174
[9] Maximizing the Impact of Human Papillomavirus Vaccination
Garland, Suzanne M.
Machalek, Dorothy A.
CLINICAL INFECTIOUS DISEASES, 2017, 65 (06) : 890 - 892
[10] Human Papillomavirus Vaccination
Markowitz, Lauri E.
Unger, Elizabeth R.
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (19) : 1790 - 1798

← 1 2 3 4 5 →